{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-10T17:24:16.016497+00:00","company":{"ticker":"ABCL","cik":1703057,"company_name":"AbCellera Biologics Inc."},"pagination":{"limit":100,"returned":23,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Government of British Columbia","detail":"other","count":1,"first_seen":"2023-05-24T23:59:59+00:00","last_seen":"2023-05-24T23:59:59+00:00","evidence_fact_ids":[148291]},{"display_name":"Government of Canada","detail":"other","count":1,"first_seen":"2023-05-24T23:59:59+00:00","last_seen":"2023-05-24T23:59:59+00:00","evidence_fact_ids":[148290]}]},"facts":[{"fact_type":"executive_change","fact_key":"cf2444eba4","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2026-07-06T18:53:55+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-06-30","interim":false,"role":"Class III Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Lynn Seely was appointed as Class III Director at AbCellera Biologics Inc..","evidence_excerpt":"On June 30, 2026, the Board of Directors (the \"Board\") of AbCellera Biologics Inc. (the \"Company\") appointed Lynn Seely, M.D as a new Class III director.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001703057-26-000037","anchor_url":"https://secwatch.observer/filing/0001703057-26-000037#claim-cf2444eba4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000037/0001703057-26-000037-index.htm"},{"fact_type":"shareholder_vote","fact_key":"928fe45c2a4f3e89b48eab1952ae529295308070","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2026-06-12T16:12:02+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-11","outcome":"passed","proposal_text":"Non-binding advisory vote on compensation of named executive officers (Say-on-Pay)","proposal_type":"say_on_pay","results":[{"broker_non_votes":"36,576,359","subject":null,"votes_abstain":"435,917","votes_against":"10,932,105","votes_for":"142,831,950","votes_withheld":null}]},"claim":"AbCellera Biologics Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers (Say-on-Pay) at the 2026-06-11 meeting.","evidence_excerpt":"The Company’s shareholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain 142,831,950 10,932,105 435,917 The broker non-votes for this Proposal 3 totaled 36,576,359 common shares.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001703057-26-000033","anchor_url":"https://secwatch.observer/filing/0001703057-26-000033#claim-928fe45c2a4f3e89b48eab1952ae529295308070","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000033/0001703057-26-000033-index.htm"},{"fact_type":"shareholder_vote","fact_key":"396c6a290c4303b7ca8becf188d7383e8ed87983","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2026-06-12T16:12:02+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-11","outcome":"passed","proposal_text":"Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"295,930","votes_against":"552,429","votes_for":"189,927,972","votes_withheld":null}]},"claim":"AbCellera Biologics Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-11 meeting.","evidence_excerpt":"The Company’s shareholders approved Proposal 2. The votes cast at the Annual Meeting were as follows: For Against Abstain 189,927,972 552,429 295,930","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001703057-26-000033","anchor_url":"https://secwatch.observer/filing/0001703057-26-000033#claim-396c6a290c4303b7ca8becf188d7383e8ed87983","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000033/0001703057-26-000033-index.htm"},{"fact_type":"shareholder_vote","fact_key":"38f0112b71f0a760b2dc8a16caa52a1bab959aea","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2026-06-12T16:12:02+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-11","outcome":"passed","proposal_text":"Election of John S. Montalbano, CFA, and Stephen R. Quake, D.Phil. as Class III directors","proposal_type":"director_election","results":[{"broker_non_votes":"36,576,359","subject":"John S. Montalbano, CFA","votes_abstain":"45,898","votes_against":"12,723,342","votes_for":"141,430,732","votes_withheld":null},{"broker_non_votes":"36,576,359","subject":"Stephen R. Quake, D.Phil.","votes_abstain":"66,956","votes_against":"5,113,056","votes_for":"149,019,960","votes_withheld":null}]},"claim":"AbCellera Biologics Inc. shareholders approved Election of John S. Montalbano, CFA, and Stephen R. Quake, D.Phil. as Class III directors at the 2026-06-11 meeting.","evidence_excerpt":"The Company’s shareholders approved the election of John S. Montalbano, CFA, and Stephen R. Quake, D.Phil., as Class III directors recommended for election in Proposal 1 at the Annual Meeting. The Company’s shareholders voted for the Class III directors as follows: Nominee For Against Abstain John S. Montalbano, CFA 141,430,732 12,723,342 45,898 Stephen R. Quake, D.Phil. 149,019,960 5,113,056 66,956 The broker non-votes for this Proposal 1 totaled 36,576,359 common shares.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001703057-26-000033","anchor_url":"https://secwatch.observer/filing/0001703057-26-000033#claim-38f0112b71f0a760b2dc8a16caa52a1bab959aea","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000033/0001703057-26-000033-index.htm"},{"fact_type":"executive_change","fact_key":"1991527ed5","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2026-06-05T16:03:46+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-06-01","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Victor Sandor was appointed as Director at AbCellera Biologics Inc..","evidence_excerpt":"On June 1, 2026, the Board of Directors (the \"Board\") of AbCellera Biologics Inc. (the \"Company\") appointed Victor Sandor as a new director.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001703057-26-000031","anchor_url":"https://secwatch.observer/filing/0001703057-26-000031#claim-1991527ed5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000031/0001703057-26-000031-index.htm"},{"fact_type":"earnings_release","fact_key":"073b71f2b7061b1af1e3bbbdc48cb077d8e23782","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2026-05-11T20:11:11+00:00","payload":{"eps_text":"$(0.14) per share on a basic and diluted basis","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$43.2 million","period_text":"first quarter of 2026","report_date":"2026-05-11","result_type":"reported_results","revenue_text":"$8.3 million"},"claim":"AbCellera Biologics Inc. reported first quarter of 2026 results: revenue $8.3 million, net income $43.2 million, EPS $(0.14) per share on a basic and diluted basis.","evidence_excerpt":"held downstream stakes in 14 molecules in the clinic understood to be progressing on March 31, 2026. Discussion of Q1 2026 Financial Results ● Revenue – Total revenue was $8.3 million, compared to $4.2 million in Q1 2025. ● Research & Development (R&D) Expenses – R&D expenses were $46.7 million, compared to $42.5 million in Q1 2025. ● Sales, General, &","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001703057-26-000027","anchor_url":"https://secwatch.observer/filing/0001703057-26-000027#claim-073b71f2b7061b1af1e3bbbdc48cb077d8e23782","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000027/0001703057-26-000027-index.htm"},{"fact_type":"auditor_change","fact_key":"82b24b842636501ce4619d6eb60d35f7fa7b0143","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2025-11-28T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Ernst & Young LLP","disagreement_text":null,"effective_date":"2025-11-24","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"AbCellera Biologics Inc. engaged Ernst & Young LLP as its auditor.","evidence_excerpt":"on November 24, 2025, the Audit Committee selected Ernst & Young LLP (\"EY\") as the Company's new independent registered public accounting firm for the fiscal year ending December 31, 2026","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001703057-25-000032","anchor_url":"https://secwatch.observer/filing/0001703057-25-000032#claim-82b24b842636501ce4619d6eb60d35f7fa7b0143","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305725000032/0001703057-25-000032-index.htm"},{"fact_type":"auditor_change","fact_key":"78efeeca7be7b291e496c9242628506e700c2653","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2025-11-28T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"KPMG LLP","disagreement_text":null,"effective_date":"2025-11-24","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"AbCellera Biologics Inc. dismissed KPMG LLP as its auditor.","evidence_excerpt":"On November 24, 2025, the Audit Committee of the Board of Directors (the \"Audit Committee\") of AbCellera Biologics Inc. (the \"Company\") approved the dismissal of KPMG LLP (\"KPMG\") as the Company's independent registered public accounting firm, effective following the completion of KPMG's audit of the Company's consolidated financial statements for the fiscal year ending December 31, 2025, and the filing of the Company's Annual Report on Form 10-K for that fiscal year.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001703057-25-000032","anchor_url":"https://secwatch.observer/filing/0001703057-25-000032#claim-78efeeca7be7b291e496c9242628506e700c2653","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305725000032/0001703057-25-000032-index.htm"},{"fact_type":"earnings_release","fact_key":"2af9583ab72c078ee81e08704e06efa4557fa51f","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":"$(0.14) per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss of $40.6 million","period_text":"quarter ended March 31, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":"$10.0 million"},"claim":"AbCellera Biologics Inc. reported quarter ended March 31, 2024 results: revenue $10.0 million, net income Net loss of $40.6 million, EPS $(0.14) per share.","evidence_excerpt":"● Revenue – Total revenue was $10.0 million, compared to $12.2 million in Q1 2023. Partnerships generated research fees of $9.8 million, compared to $10.6 million in Q1 2023. Licensing revenue was $0.2 million. ● Research & Development (R&D) Expenses – R&D expenses were $39.3 million, compared to $52.6 million in Q1 2023, reflecting underlying continued growth in program execution, platform development, and investments in internal programs, partially offset by the non-recurrence of specific one-time investments in co-development and internal programs. ● Sales & Marketing (S&M) Expenses – S&M expenses were $3.4 million, compared to $3.8 million in Q1 2023. ● General & Administrative (G&A) Expenses – G&A expenses were $17.4 million, compared to $15.1 million in Q1 2023. ● Net Loss – Net loss of $40.6 million, or $(0.14) per share on a basic and diluted basis, compared to net loss of $40.1 million, or $(0.14) per share on a basic and diluted basis in Q1 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-24-021115","anchor_url":"https://secwatch.observer/filing/0001628280-24-021115#claim-2af9583ab72c078ee81e08704e06efa4557fa51f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000162828024021115/0001628280-24-021115-index.htm"},{"fact_type":"executive_change","fact_key":"563bd50667","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2024-02-23T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"routine","effective_date":"2024-03-07","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Peter Thiel retired as Director at AbCellera Biologics Inc..","evidence_excerpt":"On February 16, 2024, Peter Thiel, a member of the Board of Directors of AbCellera Biologics Inc. (the “Company”) and the Chairman of the Nominating and Corporate Governance Committee thereof, notified the Company of his intention to retire from the Company’s Board of Directors and all committees for personal reasons, effective March 7, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001703057-24-000024","anchor_url":"https://secwatch.observer/filing/0001703057-24-000024#claim-563bd50667","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305724000024/0001703057-24-000024-index.htm"},{"fact_type":"earnings_release","fact_key":"be168079e4c8915aa451cca7e05a387e6fac4dcb","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2024-02-20T23:59:59+00:00","payload":{"eps_text":"$(0.51) per share on a basic and diluted basis","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$146.4 million, or $(0.51) per share on a basic and diluted basis","period_text":"full year 2023","report_date":"2024-02-20","result_type":"reported_results","revenue_text":"$38.0 million"},"claim":"AbCellera Biologics Inc. reported full year 2023 results: revenue $38.0 million, net income $146.4 million, or $(0.51) per share on a basic and diluted basis, EPS $(0.51) per share on a basic and diluted basis.","evidence_excerpt":"the press release is furnished herewith as Exhibit 99.1. \n\n--- EX-99.1 (EX-99.1) ---\n\nNEWS RELEASE AbCellera Reports Full Year 2023 Business Results 2/20/2024 ● Total revenue of $38 million, compared to $485 million in FY 2022 ● Total cumulative partner-initiated program starts with downstreams of 87, with 12 new starts in the year ● Net loss of $0.51 per share on a","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001703057-24-000017","anchor_url":"https://secwatch.observer/filing/0001703057-24-000017#claim-be168079e4c8915aa451cca7e05a387e6fac4dcb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305724000017/0001703057-24-000017-index.htm"},{"fact_type":"earnings_release","fact_key":"a406cdb3cc6dfb0517a24256a45e95ebf50fe31d","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2023-11-02T23:59:59+00:00","payload":{"eps_text":"$(0.10) per share on a basic and diluted basis","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of $28.6 million","period_text":"the quarter ended September 30, 2023","report_date":"2023-11-02","result_type":"reported_results","revenue_text":"$6.6 million"},"claim":"AbCellera Biologics Inc. reported the quarter ended September 30, 2023 results: revenue $6.6 million, net income net loss of $28.6 million, EPS $(0.10) per share on a basic and diluted basis.","evidence_excerpt":"value, both through strategic partnerships, and through internal discovery and development of potential first-in-class antibody therapies.” Q3 2023 Business Summary ● Earned $6.6 million in total revenue. ● Generated a net loss of $28.6 million, compared to net earnings of $26.6 million in Q3 2022. ● Reached a cumulative total of 182 programs under contract with","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001703057-23-000038","anchor_url":"https://secwatch.observer/filing/0001703057-23-000038#claim-a406cdb3cc6dfb0517a24256a45e95ebf50fe31d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000038/0001703057-23-000038-index.htm"},{"fact_type":"earnings_release","fact_key":"93362d06fb08a6634d679536e13a9af8d419efb1","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2023-08-03T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"quarter ended June 30, 2023","report_date":"2023-08-03","result_type":"reported_results","revenue_text":null},"claim":"AbCellera Biologics Inc. reported financial results for quarter ended June 30, 2023.","evidence_excerpt":"On August 3, 2023, AbCellera Biologics Inc., (the “Company”), issued a press release announcing its financial and operational results for the quarter ended June 30, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001703057-23-000020","anchor_url":"https://secwatch.observer/filing/0001703057-23-000020#claim-93362d06fb08a6634d679536e13a9af8d419efb1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000020/0001703057-23-000020-index.htm"},{"fact_type":"earnings_release","fact_key":"12babcba7544ed7a978e3c5edbcfd0eccfe44484","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2023-08-03T23:59:59+00:00","payload":{"eps_text":"$(0.11) per share on a basic and diluted basis","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$30.5 million","period_text":"the second quarter of 2023","report_date":"2023-08-03","result_type":"reported_results","revenue_text":"$10.1 million"},"claim":"AbCellera Biologics Inc. reported the second quarter of 2023 results: revenue $10.1 million, net income $30.5 million, EPS $(0.11) per share on a basic and diluted basis.","evidence_excerpt":"this funding will drive value in multiple dimensions of our business, including advancing more pre-partnered programs to the clinic.” Q2 2023 Business Summary ● Earned $10.1 million in total revenue. ● Generated a net loss of $30.5 million, compared to a net loss of $6.8 million in Q2 2022. ● Maintained a cumulative total of 177 programs under contract with","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001703057-23-000020","anchor_url":"https://secwatch.observer/filing/0001703057-23-000020#claim-12babcba7544ed7a978e3c5edbcfd0eccfe44484","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000020/0001703057-23-000020-index.htm"},{"fact_type":"shareholder_vote","fact_key":"dfc99d5971585403564800e63664bfb62209389a","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2023-06-20T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-15","outcome":"passed","proposal_text":"Approve on a non-binding advisory basis the compensation of the Company’s named executive officers (Say-on-Pay)","proposal_type":"say_on_pay","results":[{"broker_non_votes":"23,048,328","subject":null,"votes_abstain":"355,046","votes_against":"18,625,842","votes_for":"159,440,607","votes_withheld":null}]},"claim":"AbCellera Biologics Inc. shareholders approved Approve on a non-binding advisory basis the compensation of the Company’s named executive officers (Say-on-Pay) at the 2023-06-15 meeting.","evidence_excerpt":"The votes cast at the Annual Meeting were as follows: For Against Abstain 159,440,607 18,625,842 355,046 The broker non-votes for this Proposal 3 totaled 23,048,328 common shares.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001703057-23-000014","anchor_url":"https://secwatch.observer/filing/0001703057-23-000014#claim-dfc99d5971585403564800e63664bfb62209389a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000014/0001703057-23-000014-index.htm"},{"fact_type":"shareholder_vote","fact_key":"81e33ce65aaf26335d8cbd600994f15853ae5f09","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2023-06-20T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-15","outcome":"passed","proposal_text":"Ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"186,386","votes_against":"299,897","votes_for":"200,983,540","votes_withheld":null}]},"claim":"AbCellera Biologics Inc. shareholders approved Ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-15 meeting.","evidence_excerpt":"The votes cast at the Annual Meeting were as follows: For Against Abstain 200,983,540 299,897 186,386","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001703057-23-000014","anchor_url":"https://secwatch.observer/filing/0001703057-23-000014#claim-81e33ce65aaf26335d8cbd600994f15853ae5f09","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000014/0001703057-23-000014-index.htm"},{"fact_type":"shareholder_vote","fact_key":"1d73cc794ecec7aa990c77c3e346ced2a7fa102c","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2023-06-20T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-15","outcome":"passed","proposal_text":"Election of John S. Montalbano, CFA and Peter Thiel as class III directors","proposal_type":"director_election","results":[{"broker_non_votes":"23,048,328","subject":"John S. Montalbano, CFA","votes_abstain":"165,946","votes_against":"10,997,867","votes_for":"167,257,682","votes_withheld":null},{"broker_non_votes":"23,048,328","subject":"Peter Thiel","votes_abstain":"237,146","votes_against":"47,033,189","votes_for":"131,151,160","votes_withheld":null}]},"claim":"AbCellera Biologics Inc. shareholders approved Election of John S. Montalbano, CFA and Peter Thiel as class III directors at the 2023-06-15 meeting.","evidence_excerpt":"The Company’s shareholders voted for the class III directors as follows: Nominee For Against Abstain John S. Montalbano, CFA 167,257,682 10,997,867 165,946 Peter Thiel 131,151,160 47,033,189 237,146 The broker non-votes for this Proposal 1 totaled 23,048,328 common shares.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001703057-23-000014","anchor_url":"https://secwatch.observer/filing/0001703057-23-000014#claim-1d73cc794ecec7aa990c77c3e346ced2a7fa102c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000014/0001703057-23-000014-index.htm"},{"fact_type":"material_agreement","fact_key":"f34ef0a4fffcfea49d24c642e43e89c3f3a06e91","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2023-05-24T23:59:59+00:00","payload":{"action":"entry","agreement_name":"BC Contribution Agreement","agreement_type":"other","counterparty":"Government of British Columbia","effective_date":"2023-05-24","item_codes_triggered":["1.01"],"value_text":"Up to $55.6 million (CA$75.0 million) including partial reimbursement and conditional portions."},"claim":"AbCellera Biologics Inc. entered into BC Contribution Agreement with Government of British Columbia valued at Up to $55.6 million (CA$75.0 million) including partial reimbursement and conditional portions. (effective 2023-05-24).","evidence_excerpt":"Pursuant to the BC Contribution Agreement, the Government of British Columbia has committed up to $55.6 million (CA$75.0 million) which includes partial reimbursement of certain eligible expenditures up to $27.8 million (CA$37.5 million) towards eligible infrastructure investments paid over five years; and a $27.8 million (CA$37.5 million) conditional portion paid upon achievement of certain defined milestones, including upon the Company’s undertaking of certain clinical trial activities in British Columbia.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001703057-23-000011","anchor_url":"https://secwatch.observer/filing/0001703057-23-000011#claim-f34ef0a4fffcfea49d24c642e43e89c3f3a06e91","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000011/0001703057-23-000011-index.htm"},{"fact_type":"material_agreement","fact_key":"ba6c2cd2ec9cf46e88f8fd6629ea1f5e49952489","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2023-05-24T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Canada Contribution Agreement","agreement_type":"other","counterparty":"Government of Canada","effective_date":"2023-05-24","item_codes_triggered":["1.01"],"value_text":"Up to $166.7 million (CA$225.0 million) including non-repayable, repayable, and conditionally repaya"},"claim":"AbCellera Biologics Inc. entered into Canada Contribution Agreement with Government of Canada valued at Up to $166.7 million (CA$225.0 million) including non-repayable, repayable, and conditionally repaya (effective 2023-05-24).","evidence_excerpt":"Pursuant to the Canada Contribution Agreement, the Government of Canada has committed up to $166.7 million (CA$225.0 million), of which $41.6 million (CA$56.2 million) is not repayable, $58.4 million (CA$78.8 million) is repayable and $66.7 million (CA$90.0 million) is conditionally repayable.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001703057-23-000011","anchor_url":"https://secwatch.observer/filing/0001703057-23-000011#claim-ba6c2cd2ec9cf46e88f8fd6629ea1f5e49952489","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000011/0001703057-23-000011-index.htm"},{"fact_type":"earnings_release","fact_key":"bdb779054b7c3db29f00d22bc789416eda3e5aba","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2023-02-21T23:59:59+00:00","payload":{"eps_text":"$0.56 per share on a basic and $0.50 on a diluted basis","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$158.5 million, or $0.56 per share on a basic and $0.50 on a diluted basis","period_text":"the year ended December 31, 2022","report_date":"2023-02-21","result_type":"reported_results","revenue_text":"$485.4 million in total revenue"},"claim":"AbCellera Biologics Inc. reported the year ended December 31, 2022 results: revenue $485.4 million in total revenue, net income $158.5 million, or $0.56 per share on a basic and $0.50 on a diluted basis, EPS $0.56 per share on a basic and $0.50 on a diluted basis.","evidence_excerpt":"as Exhibit 99.1. \n\n--- EX-99.1 (EX-99.1) ---\n\nabcl-ex991_43.htm Exhibit 99.1 NEWS RELEASE AbCellera Reports Full Year 2022 Business Results 02/21/2023 • Total revenue of $485 million, compared to $375 million in FY 2021 • Total cumulative partnered program starts of 101, with 23 new starts in the year • Net earnings of $0.56 per share on a basic and $0.50 on","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-23-002126","anchor_url":"https://secwatch.observer/filing/0001564590-23-002126#claim-bdb779054b7c3db29f00d22bc789416eda3e5aba","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000156459023002126/0001564590-23-002126-index.htm"},{"fact_type":"earnings_release","fact_key":"b7743b387eb84823196433493ecad52189a9a14f","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2022-11-08T23:59:59+00:00","payload":{"eps_text":"$0.09 per share (basic) and $0.08 per share (diluted)","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$26.6 million","period_text":"Q3 2022","report_date":"2022-11-08","result_type":"reported_results","revenue_text":"$101.4 million"},"claim":"AbCellera Biologics Inc. reported Q3 2022 results: revenue $101.4 million, net income $26.6 million, EPS $0.09 per share (basic) and $0.08 per share (diluted).","evidence_excerpt":"Total revenue of $101 million, compared to $6 million in Q3 2021 • Four program starts in the quarter, bringing cumulative total to 92, up 33% from Q3 2021 • Net earnings of $0.09 per share on a basic and $0.08 on a diluted basis, compared to a net loss of ($0.08) per share (basic and diluted) in Q3 2021","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-22-037057","anchor_url":"https://secwatch.observer/filing/0001564590-22-037057#claim-b7743b387eb84823196433493ecad52189a9a14f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000156459022037057/0001564590-22-037057-index.htm"},{"fact_type":"executive_change","fact_key":"fd8af961eb","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2022-07-19T23:59:59+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"routine","effective_date":"2022-06-29","interim":false,"role":"Chief Business Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Neil Berkley departed as Chief Business Officer at AbCellera Biologics Inc..","evidence_excerpt":"the departure of Neil Berkley, its Chief Business Officer, from the Company effective June 29, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-22-025922","anchor_url":"https://secwatch.observer/filing/0001564590-22-025922#claim-fd8af961eb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000156459022025922/0001564590-22-025922-index.htm"},{"fact_type":"executive_change","fact_key":"5819f5b22c","cik":1703057,"ticker":"ABCL","company_name":"AbCellera Biologics Inc.","filed_at":"2022-07-06T23:59:59+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"routine","effective_date":"2022-06-29","interim":false,"role":"Chief Business Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Neil Berkley departed as Chief Business Officer at AbCellera Biologics Inc..","evidence_excerpt":"Effective June 29, 2022, Neil Berkley is no longer the Chief Business Officer of AbCellera Biologics Inc.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001564590-22-025392","anchor_url":"https://secwatch.observer/filing/0001564590-22-025392#claim-5819f5b22c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1703057/000156459022025392/0001564590-22-025392-index.htm"}]}